36.11
price down icon4.40%   -1.66
after-market After Hours: 36.11
loading
Legend Biotech Corp Adr stock is traded at $36.11, with a volume of 909.07K. It is down -4.40% in the last 24 hours and up +4.00% over the past month. Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
See More
Previous Close:
$37.77
Open:
$37.83
24h Volume:
909.07K
Relative Volume:
0.63
Market Cap:
$6.62B
Revenue:
$520.18M
Net Income/Loss:
$-348.13M
P/E Ratio:
-18.81
EPS:
-1.92
Net Cash Flow:
$-176.18M
1W Performance:
-2.98%
1M Performance:
+4.00%
6M Performance:
-34.63%
1Y Performance:
-39.22%
1-Day Range:
Value
$35.73
$38.97
1-Week Range:
Value
$35.73
$39.54
52-Week Range:
Value
$30.17
$70.13

Legend Biotech Corp Adr Stock (LEGN) Company Profile

Name
Name
Legend Biotech Corp Adr
Name
Phone
-
Name
Address
-
Name
Employee
1,800
Name
Twitter
@LegendBiotech
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
LEGN's Discussions on Twitter

Compare LEGN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
LEGN
Legend Biotech Corp Adr
36.11 6.62B 520.18M -348.13M -176.18M -1.92
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
481.16 123.91B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
722.07 78.94B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
657.97 39.98B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
278.25 35.89B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
119.94 28.75B 3.30B -501.07M 1.03B -2.1146

Legend Biotech Corp Adr Stock (LEGN) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-08-24 Initiated Redburn Atlantic Buy
Jun-17-24 Initiated Truist Buy
May-24-24 Reiterated H.C. Wainwright Buy
May-23-24 Initiated Deutsche Bank Buy
Apr-17-24 Upgrade Scotiabank Sector Perform → Sector Outperform
Apr-03-24 Initiated Cantor Fitzgerald Overweight
Mar-13-24 Initiated Raymond James Outperform
Dec-19-23 Initiated Scotiabank Sector Perform
Nov-06-23 Initiated Goldman Buy
May-25-23 Initiated William Blair Mkt Perform
May-22-23 Initiated Daiwa Securities Buy
Mar-29-23 Initiated H.C. Wainwright Buy
Mar-24-23 Initiated RBC Capital Mkts Outperform
Dec-06-22 Initiated UBS Buy
Nov-02-22 Initiated Evercore ISI Outperform
Nov-01-22 Initiated Cowen Outperform
Oct-31-22 Initiated Guggenheim Neutral
Jun-17-22 Initiated BMO Capital Markets Outperform
Mar-15-22 Initiated Barclays Overweight
Jan-31-22 Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-06-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Dec-21-21 Initiated Piper Sandler Overweight
May-18-21 Initiated BTIG Research Buy
Jul-01-20 Initiated JP Morgan Overweight
Jul-01-20 Initiated Jefferies Buy
Jun-30-20 Initiated Morgan Stanley Overweight
View All

Legend Biotech Corp Adr Stock (LEGN) Latest News

pulisher
Feb 06, 2025

Legend Biotech Corp ADR (LEGN) stock analysis: A comprehensive overview - US Post News

Feb 06, 2025
pulisher
Feb 04, 2025

Beyond Meat Inc (BYND)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex

Feb 04, 2025
pulisher
Feb 04, 2025

Deeper Dive: Understanding Legend Biotech Corp ADR (LEGN) Through its Various Ratios - The Dwinnex

Feb 04, 2025
pulisher
Feb 04, 2025

Legend Biotech Corp ADR (LEGN) looking to reclaim success with recent performance - SETE News

Feb 04, 2025
pulisher
Feb 04, 2025

CIMG Inc (IMG)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex

Feb 04, 2025
pulisher
Feb 04, 2025

Ratio Analysis: Unpacking XPLR Infrastructure LP (XIFR)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Feb 04, 2025
pulisher
Feb 04, 2025

Ratios in Focus: Analyzing Aurora Mobile Ltd ADR (JG)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Feb 04, 2025
pulisher
Feb 03, 2025

Analyze Legend Biotech Corp ADR (NASDAQ: LEGN) Before Investing. - Stocks Register

Feb 03, 2025
pulisher
Jan 28, 2025

Legend Biotech's SWOT analysis: carvykti's efficacy drives stock potential amid competition - Investing.com India

Jan 28, 2025
pulisher
Jan 24, 2025

Strength Seen in Eton Pharmaceuticals (ETON): Can Its 10.8% Jump Turn into More Strength? - Yahoo Finance

Jan 24, 2025
pulisher
Jan 22, 2025

Legend Biotech stock target cut to $91 by Jefferies - Investing.com South Africa

Jan 22, 2025
pulisher
Jan 21, 2025

Legend Biotech keeps stock at Buy rating on strong position - Investing.com India

Jan 21, 2025
pulisher
Jan 20, 2025

When will lagging health care stocks return to healthy growth? - The Globe and Mail

Jan 20, 2025
pulisher
Jan 16, 2025

Legend Biotech's SWOT analysis: carvykti's strong sales fuel stock's potential - Investing.com India

Jan 16, 2025
pulisher
Jan 16, 2025

Legend Biotech's SWOT analysis: carvykti's strong sales fuel stock's potential By Investing.com - Investing.com South Africa

Jan 16, 2025
pulisher
Jan 08, 2025

Legend Biotech's SWOT analysis: carvykti sales boost stock amid competition - Investing.com India

Jan 08, 2025
pulisher
Dec 30, 2024

Legend Biotech's SWOT analysis: carvykti's promise drives stock outlook By Investing.com - Investing.com South Africa

Dec 30, 2024
pulisher
Dec 30, 2024

Legend Biotech's SWOT analysis: carvykti's promise drives stock outlook - Investing.com India

Dec 30, 2024
pulisher
Dec 30, 2024

Overweight rating for Legend Biotech reflects confidence in long-term CARVYKTI revenue - Investing.com India

Dec 30, 2024
pulisher
Dec 19, 2024

Legend Biotech stock hits 52-week low at $32.65 amid market challenges - Investing.com

Dec 19, 2024
pulisher
Dec 15, 2024

Legend Biotech's SWOT analysis: carvykti's efficacy drives stock potential amid challenges - Investing.com India

Dec 15, 2024
pulisher
Dec 12, 2024

Legend Biotech stock hits 52-week low at $36.9 amid market shifts By Investing.com - Investing.com South Africa

Dec 12, 2024
pulisher
Dec 11, 2024

Legend Biotech stock hits 52-week low at $36.9 amid market shifts - Investing.com

Dec 11, 2024
pulisher
Dec 03, 2024

Analysts Expect ACWI To Hit $136 - Nasdaq

Dec 03, 2024
pulisher
Nov 24, 2024

Earnings call: Legend Biotech sees strong growth with CARVICTI sales - Investing.com India

Nov 24, 2024
pulisher
Nov 24, 2024

Earnings call: Legend Biotech sees robust growth with CARVICTI sales - Investing.com

Nov 24, 2024
pulisher
Nov 22, 2024

Legend Biotech Corp ADR (NASDAQ: LEGN) Has Great Upside Potential - Stocks Register

Nov 22, 2024
pulisher
Nov 22, 2024

Thinking Of Investing In Bilibili Inc ADR (NASDAQ: BILI) Stock? Read This First - Stocks Register

Nov 22, 2024
pulisher
Nov 22, 2024

Are Medtronic Plc (NYSE: MDT) Analysts Predicting A Spike? - Stocks Register

Nov 22, 2024
pulisher
Nov 21, 2024

Why Is Legend Biotech Corporation (LEGN) Among the Worst Performing Biotech Stocks in 2024? - Yahoo Finance

Nov 21, 2024
pulisher
Nov 19, 2024

Parkway Corporate Limited Announces New Securities Issuance - MSN

Nov 19, 2024
pulisher
Nov 15, 2024

Legend Biotech stock hits 52-week low at $38.59 amid market shifts - Investing.com

Nov 15, 2024
pulisher
Nov 14, 2024

Legend Biotech's SWOT analysis: stock shows promise amid CAR-T therapy growth - Investing.com India

Nov 14, 2024
pulisher
Nov 14, 2024

Legend Biotech shares steady with Overweight rating as Cantor raises target on Carvykti potential - Investing.com India

Nov 14, 2024
pulisher
Nov 14, 2024

Legend Biotech shares steady with Overweight rating as Cantor raises target on Carvykti potential By Investing.com - Investing.com South Africa

Nov 14, 2024
pulisher
Nov 12, 2024

Earnings call: Legend Biotech sees robust growth in CARVYKTI sales - Investing.com

Nov 12, 2024
pulisher
Nov 12, 2024

Legend Biotech (LEGN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN

Nov 12, 2024
pulisher
Nov 12, 2024

Legend Biotech (LEGN) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance

Nov 12, 2024
pulisher
Nov 06, 2024

T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - GlobeNewswire Inc.

Nov 06, 2024
pulisher
Nov 05, 2024

Legend Biotech's SWOT analysis: carvykti success drives stock outlook - Investing.com

Nov 05, 2024
pulisher
Nov 04, 2024

Gilead Science to Report Q3 Earnings: What's in the Cards? - Yahoo Finance

Nov 04, 2024
pulisher
Nov 04, 2024

Legend Biotech appoints new President for CARVYKTI - Investing.com

Nov 04, 2024

Legend Biotech Corp Adr Stock (LEGN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$80.78
price down icon 0.82%
$20.67
price down icon 0.53%
$353.75
price down icon 0.12%
$5.04
price down icon 2.14%
biotechnology ONC
$228.87
price up icon 0.53%
$119.94
price down icon 1.99%
Cap:     |  Volume (24h):